Silk Road Medical (NSDQ:SILK) touted results from a comparative effectiveness study of transcarotid artery revascularization (TCAR).
Results, published in JAMA Network Open, found that the availability of TCAR at a hospital was associated with a significant decrease in the likelihood of major adverse cardiovascular events, which are a composite of in-hospital stroke, myocardial infarction or death at 30 days after carotid revascularization through either TCAR or carotid endarterectomy (CEA), according to a news release.
Sunnyvale, Calif.-based Silk Road Medical’s analysis observed 86,037 patients who underwent carotid procedures between 2015 and 2019, using retrospective data from the Vascular Quality Initiative registry. In total, 7,664 patients (8.9%) underwent TCAR and 78,363 patients (91.1%) underwent CEA.
The analysis revealed that, among the more than 400 North American centers participating, 15 used both TCAR and CEA at the beginning of the analysis period. The number increased to 247 centers by the end.
The use of TCAR increased from 90 out of 12,276 procedures in 2015 to 2,718 out of 15,956 in 2019. The study showed that centers that adopted TCAR had a 10% reduction in the likelihood of major adverse cardiovascular events at 12 months than centers that continued to perform CEA alone.
“The publication of these findings in JAMA is another powerful reminder that TCAR gives the vascular specialist more options when treating carotid artery disease to the benefit of all carotid patients,” Silk Road Medical CEO Erica Rogers said in the news release. “We’re confident that as more and more practices adopt TCAR, providers will recognize the overall benefits of a less invasive approach and will further drive TCAR toward standard of care.”